ASTROTECH Corp (ASTC) stock intrinsic value fair value estimate & owner earnings analysis

Astrotech is a small Nasdaq-listed company built around a mass-spectrometry technology platform that it commercializes through separate subsidiaries. The most advanced is 1st Detect, whose TRACER 1000 narcotics and explosives trace detector was added to the TSA's Air Cargo Security Technology List in June 2024 and won a Department of Homeland Security research contract in January 2025; the product made its first commercial sale, in Vietnam, in June 2025. A second subsidiary, AgLAB, sells mass spectrometers used by hemp and cannabis processors to optimize extraction yields (the company does not grow or sell cannabis itself). A third, smaller line serves industrial and environmental testing. Despite these developments, the underlying financial picture has not improved. Revenue was just $1.0 million in the fiscal year ended June 2025, down from $1.7 million the year before, while the company spent roughly $13 million funding operations and building manufacturing capacity - a loss that has widened, not narrowed, over the past year. This is not a new pattern: in every one of the last ten fiscal years the business has consumed more cash than it generated. A large equity raise in 2021 (roughly $68 million gross) funded this stretch, but that capital has been spent down steadily since: shareholders' equity, mostly held in cash and short-term investments, fell from about $61 million in mid-2021 to about $22 million a year ago and, per the company's most recent unaudited quarterly figures, to roughly $12 million by March 2026 - with cash on hand alone down to about $2.7 million against quarterly spending of a similar order. On that trend, the company is likely to need new outside financing within the next several quarters to keep funding operations. We searched the most recent annual report for a formal going-concern warning and found none, but we were not able to review the text of the most recent quarterly filing (only its financial figures were available to us), so we flag this cash trajectory plainly rather than assume it has been resolved. Because the business has never generated positive owner earnings and its yearly cash burn is large relative to its roughly 1.7 million shares outstanding, we anchor our valuation on what the company actually holds today - its net cash and investments, worth approximately $7 per share - and then weigh how much of that is likely to survive continued operating losses before any commercial payoff arrives, rather than projecting an indefinite loss stream at face value. Our base case assumes slow, uneven commercialization: the TSA listing and DHS contract produce some revenue growth, but government and airport sales cycles are slow, at least one more dilutive capital raise is likely over the next two years, and the business does not clearly reach sustained profitability within a decade. That leaves the shares worth a fraction of today's cash value, around $3 per share. Our bear case assumes the TSA and DHS relationships do not convert to real orders in time, cash runs out within the next year or so, and a distressed, heavily discounted financing (or a forced sale of the technology) leaves today's shareholders with only a small residual value, around $0.75 per share. Our bull case assumes the TSA approval - already in hand - turns into actual procurement contracts with airports and cargo handlers over the next several years, AgLAB and the industrial testing line gain real traction, and the company reaches sustained profitability without further heavy dilution, which would make the shares worth meaningfully more than today's cash alone, around $13. In building this estimate we treated stock-based compensation as a real cost (subtracted, not added back), and we added back depreciation, lease-related non-cash items, and one-time impairment or disposal charges as non-operating. We used a fixed 6% discount rate throughout, with risk reflected only in the width of the bear-to-bull range, not in the rate. Given the combination of a very small revenue base, a shrinking cash cushion, and a decade of losses, the margin-of-safety price sits at a meaningful discount to our base-case estimate, and it is best supported once there is concrete evidence - a signed contract or non-dilutive financing - that the cash burn is under control.